Compass Therapeutics Statistics
Total Valuation
CMPX has a market cap or net worth of $371.88 million. The enterprise value is $187.89 million.
| Market Cap | 371.88M |
| Enterprise Value | 187.89M |
Important Dates
The next estimated earnings date is Monday, August 10, 2026, before market open.
| Earnings Date | Aug 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CMPX has 180.09 million shares outstanding. The number of shares has increased by 23.18% in one year.
| Current Share Class | 180.09M |
| Shares Outstanding | 180.09M |
| Shares Change (YoY) | +23.18% |
| Shares Change (QoQ) | +0.84% |
| Owned by Insiders (%) | 5.85% |
| Owned by Institutions (%) | 73.92% |
| Float | 122.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.03 |
| P/TBV Ratio | 2.00 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 19.04, with a Debt / Equity ratio of 0.05.
| Current Ratio | 19.04 |
| Quick Ratio | 18.94 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -45.95% and return on invested capital (ROIC) is -30.03%.
| Return on Equity (ROE) | -45.95% |
| Return on Assets (ROA) | -27.91% |
| Return on Invested Capital (ROIC) | -30.03% |
| Return on Capital Employed (ROCE) | -38.57% |
| Weighted Average Cost of Capital (WACC) | 8.09% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.75M |
| Employee Count | 39 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.92% in the last 52 weeks. The beta is 0.74, so CMPX's price volatility has been lower than the market average.
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -12.92% |
| 50-Day Moving Average | 2.70 |
| 200-Day Moving Average | 4.42 |
| Relative Strength Index (RSI) | 44.04 |
| Average Volume (20 Days) | 4,039,165 |
Short Selling Information
The latest short interest is 33.27 million, so 18.47% of the outstanding shares have been sold short.
| Short Interest | 33.27M |
| Short Previous Month | 31.02M |
| Short % of Shares Out | 18.47% |
| Short % of Float | 27.12% |
| Short Ratio (days to cover) | 4.31 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -75.17M |
| Pretax Income | -68.17M |
| Net Income | -68.17M |
| EBITDA | -75.02M |
| EBIT | -75.17M |
| Earnings Per Share (EPS) | -$0.40 |
Balance Sheet
The company has $194.69 million in cash and $9.79 million in debt, with a net cash position of $184.90 million or $1.03 per share.
| Cash & Cash Equivalents | 194.69M |
| Total Debt | 9.79M |
| Net Cash | 184.90M |
| Net Cash Per Share | $1.03 |
| Equity (Book Value) | 186.47M |
| Book Value Per Share | 1.04 |
| Working Capital | 185.41M |
Cash Flow
In the last 12 months, operating cash flow was -$53.20 million and capital expenditures -$89,000, giving a free cash flow of -$53.29 million.
| Operating Cash Flow | -53.20M |
| Capital Expenditures | -89,000 |
| Depreciation & Amortization | 151,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -53.29M |
| FCF Per Share | -$0.30 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CMPX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.18% |
| Shareholder Yield | -23.18% |
| Earnings Yield | -18.29% |
| FCF Yield | -14.30% |
Analyst Forecast
The average price target for CMPX is $8.82, which is 327.12% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.82 |
| Price Target Difference | 327.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |